<DOC>
	<DOCNO>NCT02253459</DOCNO>
	<brief_summary>The purpose study determine whether UTD1 Injection combination capecitabine effective treatment advance metastatic breast cancer use capecitabine control .</brief_summary>
	<brief_title>Clinical Study UTD1 Injection Combination With Capecitabine Patients With Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Histologically and/or cytologically diagnosed patient advance , metastatic breast cancer , lack standard therapy fail recurrent standard therapy ; 2 . Patients previously treat ≤4 chemotherapeutic regime ; 3 . Patients previously treat anthracyclin antibiotic taxane ; 4 . Age 18 70 year old , ECOG performance status 02 ; Life expectancy 3 month ; 5 . Patients least 1 measurable target lesion determine CT within 2 week prior enrollment ; 6 . Neuropathy ＜CTC2 degree （NCI CTC4.03）within 4 week prior enrollment ; 7 . Basically normal result routine blood test within 1 week prior enrollment ; 8 . Basically normal liver renal function within 1 week prior enrollment ; 9 . No abnormal function major internal organ , heart disease . 1 . Received chemotherapy , radiotherapy , therapy hormones molecularly target drug 4 week prior enrollment , receive chemotherapy participate trial ; 2 . Patients documented hypersensitivity Cremophor EL , patient previous taxane treatment related SAE ; 3 . Patients pregnancy breast feeding ; 4 . Patients previous standard capecitabine treatment ineffective , patient receive standard capecitabine treatment effective , less 6 month capecitabine clearance period ; 5 . Patients uncontrolled brain metastasis bone metastasis , plan recent surgery local radiotherapy , emergency treatment ; 6 . Patients combine severe /or uncontrolled medical condition , include severe cardiovascular disease , uncontrolled diabetes high blood pressure , severe infection , severe gastrointestinal ulceration , patient incontrollable psychiatric history ; 7 . Patients poor compliance ; 8 . Patients fit study determine investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>